Partnership Opportunities

Following a year of a huge influx in investment with partnerships and acquisitions specifically directed at developing novel vectors, the 5th Next Generation Gene Therapy Vectors Summit returns as a unique opportunity to connect with a targeted group of vector experts to improve safety and targeting. Tap into this dedicated community of vector engineers, preclinical experts, and business development leaders to showcase your partnering capabilities and robust solutions to support their translation to the clinic.

With gene therapy vectors having a pre-disposition to safety and efficacy complexities, these vector developers seek reliable, time- and cost-effective solutions for vector manufacturing, preclinical models, biodistribution monitoring, and payload design optimization. Can you help?

This forum contains such a specific audience comprised of senior decision-makers and commercial leaders at the forefront of vector development, providing the ideal environment to highlight your solution and capabilities as the go-to in this space.

Why Partner?

Meet & Build Relationships with Senior Industry Experts

Meet & Build Relationships with Senior Industry Experts

Network directly with your target clients in a niche setting as decision-makers from preclinical development, translation, CMC, and more come together under one roof!

Educate this Community

Educate this
Community

Leverage a speaking position to showcase your capabilities and inform this engaged audience on how you can support their needs

Gain Brand Visibility

Gain Brand
Visibility

Elevate your brand presence and stand out from competitors to make a lasting impression on gene therapy vector developers

Gain Exclusive Market Insights

Gain Exclusive
Market Insights

Stay ahead with exclusive insider knowledge on the latest breakthroughs to ensure you keep up with your target market’s needs

Ralf Schmid

It is crucial to continuously improve gene therapies for better safety, efficacy, and cost-effectiveness. I think this summit will bring the key stakeholders together to achieve this goal.

Ralf Schmid, Associate Director, Preclinical Research, Novartis

Our 2025 Partners: